Physician profile
Kathy Chen
NPI 1871255927
$3,591.48
in general payments reported to CMS, 2019-2025
15 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $524 · 2023: $839 · 2024: $1,109 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,050 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,050.19 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,215.10 | 2022-2025 | |
| Genzyme Corporation | $392.17 | 2022-2025 | |
| Glaxosmithkline, LLC. | $309.99 | 2022-2023 | Trelegy Ellipta, Nucala |
| Amgen INC. | $260.76 | 2023 | Otezla |
| Incyte Corporation | $256.65 | 2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $253.78 | 2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $234.75 | 2022-2025 | Dupixent |
| Leo Pharma INC. | $200.50 | 2025 | Adbry |
| Lilly USA, LLC | $147.86 | 2024-2025 | Olumiant, Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $134.38 | 2024 | Sotyktu |
| Ucb, INC. | $54.87 | 2023-2025 | Bimzelx |
| Astrazeneca Pharmaceuticals LP | $47.74 | 2022 | |
| Merz North America, INC. | $41.60 | 2023-2024 | |
| Pfizer INC. | $21.49 | 2023 | |
| Novartis Pharmaceuticals Corporation | $19.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.